Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Xenon Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01486446
First received: December 2, 2011
Last updated: March 10, 2014
Last verified: March 2014
  Purpose

This is a Phase 2a single-center, randomized, double-blind, Placebo-controlled, parallel group study with XPF-002 applied twice daily over 14 or 21 days in patients with Primary/Inherited Erythromelalgia (IEM). The purpose of this study is to determine whether XPF-002 is safe and effective in the treatment of pain caused by IEM.


Condition Intervention Phase
Primary Erythromelalgia
Inherited Erythromelalgia
Drug: XPF-002
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia

Resource links provided by NLM:


Further study details as provided by Xenon Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 [ Time Frame: 14-21 Days ] [ Designated as safety issue: No ]

    Using diary cards, subjects recorded the use of all non-pharmacological cooling methods used to relieve their erythromelalgia (EM) pain each day during Treatment Period 2.

    A smaller average number of cooling uses each day in Treatment Period 2 indicates that subjects were in less pain/required less use of cooling to relieve their EM pain and vice versa.



Other Outcome Measures:
  • Average Cooling Duration (Minutes Per Day) for EM-related Pain in Treatment Period 2 [ Time Frame: 14-21 Days ] [ Designated as safety issue: No ]

    Using diary cards, subjects recorded the use and duration of all non-pharmacological cooling methods used to relieve their EM pain each day during Treatment Period 2.

    A smaller average duration of cooling each day in Treatment Period 2 indicates that subjects were in less pain/required less use of cooling to relieve their EM pain and vice versa.


  • Time to Exit (Minutes) From Standard Heat Inductions in Treatment Period 1, Compared to Baseline [ Time Frame: Baseline to Day 5 ] [ Designated as safety issue: No ]

    A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure.

    The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable. A stopwatch was used to record the time the heating procedure was stopped. This time is known as "Time to Exit".

    A longer Time to Exit compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment.


  • Time to Exit (Minutes) From Standard Heat Inductions in Treatment Period 2, Compared to Baseline [ Time Frame: Baseline and 14 or 21 days ] [ Designated as safety issue: No ]

    A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure.

    The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable. A stopwatch was used to record the time the heating procedure was stopped. This time is known as "Time to Exit".

    A longer Time to Exit compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment.


  • Time to Moderate Pain (Minutes) During Standard Heat Inductions in Treatment Period 1, Compared to Baseline [ Time Frame: Baseline to Day 5 ] [ Designated as safety issue: No ]

    A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure.

    The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable.

    A stopwatch was used to record the time the subject recorded a pain intensity numerical score of 5 or more (on a scale of 0-10). This time is known as "Time to Moderate Pain".

    A longer Time to Moderate Pain compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment.


  • Time to Moderate Pain (Minutes) During Standard Heat Inductions in Treatment Period 2, Compared to Baseline [ Time Frame: Baseline and 14 or 21 days ] [ Designated as safety issue: No ]

    A standard heat induction was performed on multiple occasions pre-and post treatment. Subjects placed their feet in front of an electric heater for up to 75 minutes. Subjects rated their pain intensity/severity using numerical and categorical rating scales at fixed intervals before, during and after the heating procedure.

    The heating procedure continued until one of the pre-defined stopping criteria were met, or when the 75 minutes were over. Subjects could stop the procedure at any time if pain was intolerable.

    A stopwatch was used to record the time the subject recorded a pain intensity numerical score of 5 or more (on a scale of 0-10). This time is known as "Time to Moderate Pain".

    A longer Time to Moderate Pain compared to Baseline indicates that subjects were able to tolerate the heat for a longer period when on treatment.


  • Daily Pain (Maximum Pain Intensity) in Treatment Period 2, Compared to Baseline [ Time Frame: Baseline to 14 or 21 days ] [ Designated as safety issue: No ]

    During Baseline and Treatment Period 2, subjects recorded pain scores in their diary cards 3 times each day (upon waking, lunchtime and evening).

    On each recording occasion, subjects recorded the maximum pain experienced since the previous recording occasion using an 11 point numerical rating scale of pain intensity, PINRS (where 0 = no pain and 10 = worst pain imaginable).

    A lower score compared to Baseline indicates that the subjects experienced less severe pain on treatment than during Baseline.


  • Sleep Interference Due to Pain in Treatment Period 2, Compared to Baseline [ Time Frame: Baseline to 14 or 21 days ] [ Designated as safety issue: No ]

    During Baseline and Treatment Period 2, subjects recorded sleep interference scores in their diary cards for each night (scores were recorded upon waking).

    Sleep Interference due to pain is scored using an 11 point numerical rating scale where 0 = pain does not interfere with sleep and 10 = completely interferes, unable to sleep due to pain.

    A lower sleep interference score compared to Baseline indicates that the subjects' pain interfered with sleep less on treatment than during Baseline.



Enrollment: 8
Study Start Date: December 2011
Study Completion Date: May 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: XPF-002
XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
Drug: XPF-002
XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
Placebo Comparator: Placebo
XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
Drug: Placebo
XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.

Detailed Description:

Your role in the study would include:

  • Travelling to the clinic (in Anniston, Alabama, USA) for 3 out-patient visits, each lasting approximately 1 day
  • Travelling and staying in the clinic for 2 in-patient stays:
  • For the first in-patient visit you will have to spend 8 days and 7 nights in the clinic
  • For the second in-patient visit you will have to spend 2 days and 1 night in the clinic You can bring books, laptops and DVDs to the clinic.

If you do not live within driving distance to the clinic you will need to stay in the local area (in Anniston, at a local hotel) for 1 to 2 weeks while you use the ointment, in addition to the in-patient portion of the study.

  Eligibility

Ages Eligible for Study:   19 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have a Body Mass Index (BMI) of 18-40 kg/m2 (inclusive)
  • Have primary or inherited erythromelalgia (IEM)
  • Experience flares of pain in your feet or hands caused by erythromelalgia
  • Be generally healthy (apart from your pain)
  • Stop taking your usual pain medications and certain other medications for up to 11.5 weeks
  • Not be pregnant or breast-feeding
  • Must be able and willing to provide informed consent and willing to comply with all study procedures and restrictions

Exclusion Criteria:

  • Must not be in constant pain (must not continually be in moderate pain, 3/10 or more)
  • Coexistent source of pain from other conditions that may interfere with the study interpretation
  • HIV, Hepatitis B or C
  • Treatment for significant depression within 6 months of Screening
  • Not willing to use adequate contraception
  • Alcoholism, alcohol or substance abuse
  • Presence or history of major psychiatric disturbance
  • Any other condition or finding that may pose undue risk for participation
  • Use of any other investigational drug in the 30 days prior to dosing
  • Donation or loss of whole blood or plasma prior to dosing as follows: 50 mL to 499 mL within 30 days, or more than 499 mL within 56 days
  • Employee or relative of an employee who is directly involved in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01486446

Locations
United States, Alabama
Pinnacle Research Group, LLC.
Anniston, Alabama, United States, 36201
Sponsors and Collaborators
Xenon Pharmaceuticals Inc.
Investigators
Principal Investigator: Almena L Free, MD Pinnacle Research Group LLC.
  More Information

No publications provided

Responsible Party: Xenon Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT01486446     History of Changes
Other Study ID Numbers: XPF-002-202
Study First Received: December 2, 2011
Results First Received: January 21, 2014
Last Updated: March 10, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Xenon Pharmaceuticals Inc.:
IEM
EM
Erythromelalgia
Erythermalgia
Red neuralgia
Peripheral Vascular Disease
Vascular Disease
Cardiovascular Disease

Additional relevant MeSH terms:
Erythromelalgia
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 28, 2014